Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Delavirdine
See also Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
General information
Delavirdine is a non-nucleoside reverse transcriptase inhibitor, which is dosed three times daily. No food restrictions apply. It is metabolized mainly by CYP3A, and so interactions with other drugs that use this metabolic pathway can occur.
Organs and systems
Skin
The most frequent adverse effect of delavirdine is a rash, which usually occurs during the first 3 months of therapy in up to 50% of individuals. It is usually mild and resolves spontaneously in most patients or can be treated successfully with a short course of antihistamines. Interruption of treatment is required in less than 4% of patients [ , ].
You're Reading a Preview
Become a Clinical Tree membership for Full access and enjoy Unlimited articles
If you are a member. Log in here